Semaglutide attenuates doxorubicin-induced cardiotoxicity by ameliorating BNIP3-Mediated mitochondrial dysfunction
Redox Biology · 2024-06 · 72 · 103129
DOI: 10.1016/j.redox.2024.103129 ↗Kurz gefasst
Fachartikel in der Zeitschrift Redox Biology, 2024-06. Verfasst von Xiaoping Li und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Daping Hospital, Third Military Medical University (Army Medical University), Chongqing, China; Key Laboratory of Geriatric…. Hauptthemen laut MEDLINE: Cardiotoxicity, Doxorubicin, Membrane Proteins, Glucagon-Like Peptides. Die Arbeit wurde bisher 74-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
AIMS: Doxorubicin is a powerful chemotherapeutic agent for cancer, whose use is limited due to its potential cardiotoxicity. Semaglutide (SEMA), a novel analog of glucagon-like peptide-1 (GLP-1), has received widespread attention for the treatment of diabetes. However, increasing evidence has highlighted its potential therapeutic benefits on cardiac function. Therefore, the objective of this study was to examine the efficacy of semaglutide in ameliorating doxorubicin-induced cardiotoxicity. METHODS AND RESULTS: Doxorubicin-induced cardiotoxicity is an established model to study cardiac function. Cardiac function was studied by transthoracic echocardiography and invasive hemodynamic monitoring. The results showed that semaglutide significantly ameliorated doxorubicin-induced cardiac dysfunction. RNA sequencing suggested that Bnip3 is the candidate gene that impaired the protective effect of semaglutide in doxorubicin-induced cardiotoxicity. To determine the role of BNIP3 on the effect of semaglutide in doxorubicin-induced cardiotoxicity, BNIP3 with adeno-associated virus serotype 9 (AAV9) expressing cardiac troponin T (cTnT) promoter was injected into tail vein of C57/BL6J mice to overexpress BNIP3, specifically in the heart. Overexpression of BNIP3 prevented the improvement in cardiac function caused by semaglutide. In vitro experiments showed that semaglutide, via PI3K/AKT pathway, reduced BNIP3 expression in the mitochondria, improving mitochondrial function. CONCLUSION: Semaglutide ameliorates doxorubicin-induced mitochondrial and cardiac dysfunction via PI3K/AKT pathway, by reducing BNIP3 expression in mitochondria. The improvement in mitochondrial function reduces doxorubicin-mediated cardiac injury and improves cardiac function. Therefore, semaglutide is a potential therapy to reduce doxorubicin-induced acute cardiotoxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Daping Hospital, Third Military Medical University (Army Medical University), Chongqing, China; Key Laboratory of Geriatric Cardiovascular and Cerebrovascular Disease Research, Ministry of Educ…
- Department of Cardiology, Daping Hospital, Third Military Medical University (Army Medical University), Chongqing, China; College of Bioengineering, Chongqing University, Chongqing, China.
- Department of Biomedical Sciences, City University of Hong Kong, Hong Kong Special Administrative Region, China.
- Division of Renal Diseases & Hypertension, The George Washington University School of Medicine & Health Sciences, Washington, DC, USA.
- Endocrinology Department, The First Affiliated Hospital of the Third Military Medical University (Army Medical University), Chongqing, China. Electronic address: dearpeardog@126.com.
Zitieren
APA
Li, X., Luo, W., Tang, Y., Wu, J., Zhang, J., Chen, S., Zhou, L., Tao, Y., Tang, Y., Wang, F., Huang, Y., Jose, P. A., Guo, L., & Zeng, C. (2024). Semaglutide attenuates doxorubicin-induced cardiotoxicity by ameliorating BNIP3-Mediated mitochondrial dysfunction. Redox Biology, 72, 103129. https://doi.org/10.1016/j.redox.2024.103129
Vancouver
Li X, Luo W, Tang Y, Wu J, Zhang J, Chen S, et al. Semaglutide attenuates doxorubicin-induced cardiotoxicity by ameliorating BNIP3-Mediated mitochondrial dysfunction. Redox Biology. 2024;72:103129. doi:10.1016/j.redox.2024.103129
BibTeX
@article{Li2024,
author = {Li, Xiaoping and Luo, Wenbin and Tang, Yang and Wu, Jiangjiao and Zhang, Junkai and Chen, Shengnan and Zhou, Lu and Tao, Yu and Tang, Yuanjuan and Wang, Fengxian and Huang, Yu and Jose, Pedro A and Guo, Li and Zeng, Chunyu},
title = {Semaglutide attenuates doxorubicin-induced cardiotoxicity by ameliorating BNIP3-Mediated mitochondrial dysfunction},
journal = {Redox Biology},
year = {2024},
volume = {72},
pages = {103129},
doi = {10.1016/j.redox.2024.103129}
}
EUVIMED